ClinicalTrials.gg
CompletedNCT01084252Updated Nov 1, 2024Results posted

Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

A Phase 1/2 interventional study of Isatuximab SAR650984 and Dexamethasone in Hematological Malignancy, sponsored by Sanofi. Completed at 59 sites in 17 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-01.

Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
351
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 821 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 276 under way, 12 of them phase 3. Hematologic Neoplasms · United States.

Enrollment
40th of 658
351 · median 40
Started
2010
with 22 others
Phase 1/2
81 of 821
16 open now
Registered
156th of 821
by date

Among the 821 studies in Hematologic Neoplasms with a site in United States, this one is the 40th largest by enrollment of the 658 interventional ones that give a count, is one of 23 that started in 2010, is one of 81 in phase 1/2, and was the 156th registered.

Hematologic Neoplasms

1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

181 of the 821 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

176 more — sign in →

All 181 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 821 studies in Hematologic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Primary Objective:

Phase 1:

To determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) of SAR650984 (Isatuximab).

Phase 2 (stage 1):

To evaluate the activity of single-agent Isatuximab at different doses/schedules and to select dose and regimen to further evaluate the overall response rate (ORR) of Isatuximab as single agent or in combination with dexamethasone.

Phase 2 (stage 2):

To evaluate the activity in terms of overall response rate (ORR) of Isatuximab at the selected dose/schedule from stage1, as single agent (ISA arm) and in combination with dexamethasone (ISAdex arm).

Secondary Objectives:

Phase 1:

  • To characterize the global safety profile including cumulative toxicities.
  • To evaluate the pharmacokinetic (PK) profile of Isatuximab in the proposed dosing schedule(s).
  • To assess the pharmacodynamics (PD), immune response, and preliminary disease response.

Phase 2 (stage 1): to evaluate the following objectives for Isatuximab as single agent:

  • Safety
  • Efficacy as measured by duration of response, clinical benefit rate, progression free survival, overall survival.

Phase 2 (stage 2): to evaluate the following objectives in each arm (ISA and ISAdex):

  • Safety
  • Efficacy as measured by duration of response, clinical benefit rate, progression free survival, overall survival.
  • Participant-reported changes in health-related quality of life, symptoms of multiple myeloma and generic health status.
  • Pharmacokinetic profile of Isatuximab.
  • Immunogenicity of Isatuximab.
  • Investigate the relationship between CD38 receptor density and CD38 receptor occupancy (Stage 1 only) on multiple myeloma cells and parameters of clinical response.
Read the detailed description

The Phase 1 study duration for an individual participant included a screening period for inclusion of up to 2 weeks, treatment with Isatuximab QW (every week) or Q2W (every 2 weeks) unless discontinued earlier due to safety or disease progression. Participants were followed for a minimum of 30 days following the last use of study drug or more than 30 days in case of unresolved toxicity, or up to initiation of another anticancer treatment.

The Phase 2 study duration for an individual participant included a screening period for inclusion of up to 3 weeks, then a treatment period and a follow up period. Treatment was continued until disease progression, unacceptable adverse reactions or other reasons for discontinuation. Participants were followed every 3 months following the last use of study drug until death or study cutoff, whichever came first.

03

Conditions studied

  • Hematological Malignancy

Keywords

  • Anti-CD38 monoclonal antibody
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phase 1:

  • For dose escalation cohorts, participants with confirmed selected CD38+ hematological as specified below who had progressed on after standard therapy or for whom there was no effective standard therapy (/relapsed participants). B-cell Non-Hodgkin-lymphoma/leukemia (NHL) participants with at least 1 . Multiple myeloma (MM) participants with measurable M-protein serum and/or 24-hour urine. Acute myeloid leukemia (AML) participants, all types except M3 based on French-American-British (FAB) classification. Acute Lymphoblastic Leukemia (B-cell ALL) participants. Chronic lymphocytic leukemia (CLL) participants.
  • For expansion cohorts, participants with relapsed/refractory MM with measurable M-protein (serum M-protein of >0.5 g/dL and/or urine M-protein of >200 mg (24-hr urine)) or elevated serum free light chains (FLC) >10 mg/dL with abnormal FLC ratio) who had progressed on or after standard therapy that included an Immunomodulatory drug (IMiD) and a proteasome inhibitor and who met the protocol defined criteria for standard risk or high risk.

Phase 2:

  • Participants had a known diagnosis of multiple myeloma with evidence of measurable disease, and have evidence of disease progression based on International Myeloma Working Group (IMWG) criteria: Serum M-protein ≥1 g/dL, or urine M-protein >=200 mg/24 hours or in the absence of measurable m-protein, serum FLC >=10 mg/dL, and abnormal serum immunoglobulin kappa lambda FLC ratio (\<0.26 or >1.65).
  • Participants who received at least three for MM and had treatment with an IMiD (for >=2 cycles or >=2 months of treatment) and a proteasome inhibitor (PI) (for >=2 cycles or >=2 months of treatment) OR participants whose disease was double refractory to an IMiD and a PI. For participants who had received more than 1 type of IMiD and PI, their disease must be refractory to the most recent one.
  • Participants who had achieved a minimal response or better to at least one prior line of therapy.
  • Participants who had received an alkylating agent (>=2 cycles or >=2 months) either alone or in combination with other MM treatments.
  • Stage 2 only: Participants who had evidence of disease progression on or after the most recent prior regimen based on IMWG criteria.

Exclusion criteria

Exclusion criteria:

Phase 1:

  • performance status \<60
  • Poor bone marrow reserve
  • Poor organ function
  • Known intolerance to infused protein products, sucrose, histidine, polysorbate 80 or known to any of the components of the study therapy that was not amenable to pre-medication with and H2 blockers
  • Any serious active disease (including infection that was chronic, recurrent, or active) or co-morbid condition, which, in the opinion of the investigator, interfered with the safety, the compliance with the study or with the interpretation of the results
  • Any severe underlying medical conditions including presence of laboratory abnormalities, which could impair the ability to participate in the study or the interpretation of its results

Phase 2:

  • Participants with multiple myeloma immunoglobulin M (IgM) subtype
  • Previous treatment with any anti-CD38 therapy
  • Participants with concurrent plasma cell leukemia
  • Participants with known or suspected amyloidosis
  • Karnofsky performance status \<60 (stage 1)/ (ECOG) Performance status >2 (stage 2).
  • Poor bone marrow reserve
  • Poor organ function
  • Known intolerance to infused protein products, sucrose, histidine, polysorbate 80 or known hypersensitivity to any of the components of the study therapy that was not amenable to pre-medication with steroids and H2 blockers
  • Any serious active disease (including clinically significant infection that was chronic, recurrent, or active) or co-morbid condition, which, in the opinion of the investigator, interfered with the safety, the compliance with the study or with the interpretation of the results
  • Any severe underlying medical conditions including presence of laboratory abnormalities, which impaired the ability to participate in the study or the interpretation of its results

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
351 participants (actual)

Study arms

  • Experimental
    Phase 1:Isatuximab <=1 mg/kg Q2W

    Participants with CD38+ hematological malignancies (HM), received Isatuximab at any one of the dose less than or equal to (\<=) 1 milligram per kilogram (mg/kg) (i.e. either 0.0001 mg/kg or 0.001 mg/kg or 0.01 mg/kg or 0.03 mg/kg or 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg) as intravenous (IV) infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).

    Drug: Isatuximab SAR650984

  • Experimental
    Phase 1: Isatuximab 3mg/kg Q2W

    Participants with CD38+ HM, received Isatuximab 3 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).

    Drug: Isatuximab SAR650984

  • Experimental
    Phase 1: Isatuximab 5 mg/kg Q2W

    Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).

    Drug: Isatuximab SAR650984

  • Experimental
    Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)

    Participants with CD38+ HM along with participants with standard risk multiple myeloma were included this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).

    Drug: Isatuximab SAR650984

  • Experimental
    Phase 1:Isatuximab (CD38 + HM and High Risk Multiple Myeloma)

    Participants with CD38+ HM along with participants with high risk multiple myeloma, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).

    Drug: Isatuximab SAR650984

  • Experimental
    Phase 1: Isatuximab 10 mg/kg QW

    Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).

    Drug: Isatuximab SAR650984

  • Experimental
    Phase 1: Isatuximab 20 mg/kg Q2W

    Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).

    Drug: Isatuximab SAR650984

  • Experimental
    Phase 1: Isatuximab 20 mg/kg QW

    Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).

    Drug: Isatuximab SAR650984

  • Experimental
    Phase 2 Stage 1a: Isatuximab 3 mg/kg Q2W

    Participants with multiple Myeloma received Isatuximab 3 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable adverse event (AE), disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 414 weeks).

    Drug: Isatuximab SAR650984

  • Experimental
    Phase 2 Stage 1a: Isatuximab 10 mg/kg Q2W

    Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 414 weeks).

    Drug: Isatuximab SAR650984

  • Experimental
    Phase2 Stage1a:Isatuximab 10mg/kg Q2W; Then Q4W

    Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion Q2W, i.e. on Day 1 and Day 15 of Cycle 1 and 2 (each cycle 28 days), then every 4 week (Q4W), i.e. on Day 1 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 414 weeks).

    Drug: Isatuximab SAR650984

  • Experimental
    Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W

    Participants with multiple Myeloma received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1, 8, 15 and 22 of Cycle 1 and 2 (each cycle 28 days), then Q2W, i.e. on Day 1 and Day 15 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 92 weeks).

    Drug: Isatuximab SAR650984

  • Experimental
    Phase 2 Stage 2: Isatuximab Alone

    Participants with relapsed or relapsed/refractory multiple myeloma (RRMM), received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator's decision (maximum exposure: 301 weeks).

    Drug: Isatuximab SAR650984

  • Experimental
    Phase 2 Stage 2: Isatuximab + Dexamethasone

    Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion (40 mg/day for less than \[\<\] 75 years of age; 20 mg/day \[greater than or equal to \[\>=\] for 75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator's decision (maximum exposure: 301 weeks).

    Drug: Isatuximab SAR650984 · Drug: Dexamethasone

Interventions

  • Pharmaceutical form: solution for infusion Route of administration: intravenous

    Also known as: Sarclisa

  • Pharmaceutical form: solution for infusion Route of administration: intravenous

  • Pharmaceutical form: tablet Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)

    DLTs were assessed using the national cancer institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03. DLTs were defined as any Grade 3 or higher non-hematological toxicity (with the exception of allergic reaction/hypersensitivity), Grade 4 neutropenia and/or Grade 4 thrombocytopenia lasting longer than 5 days, attributed to isatuximab. Any other toxicity that the Investigator and the Sponsor deemed to be dose-limiting, regardless of the grade, was also considered as DLT.

    Time frame: Day 1 of Cycle 1 up to Day 14 of Cycle 2

  2. Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.

    Time frame: From Baseline up to 30 days after the last dose (maximum duration: 120 weeks )

  3. Phase 2 Stage 1: Percentage of Participants With Overall Response (OR) According to International Myeloma Working Group (IMWG) Uniform Response Criteria

    OR defined as participants with stringent complete response (sCR) or complete response (CR) or very good partial response (VGPR) or partial response (PR) . Based on IMWG, CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and \<=5% plasma cells in bone marrow; sCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; PR: \>=50% reduction of serum M-Protein and reduction in urinary M-protein by \>=90% or to \<200 mg/24 hours; \>=50% decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria or a \>=50% reduction in plasma cells in place of M-protein if present at baseline.

    Time frame: From the date of randomization until disease progression or death or data cut-off (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for Stage 1b arm)

  4. Phase 2 Stage 2: Percentage of Participants With Overall Response According to Updated IMWG Response Criteria

    OR: participants with sCR or CR or VGPR or PR. As per updated IMWG, CR: Negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \<=5% plasma cells in bone marrow; normal FLC ratio of 0.26-1.65 in participants with only FLC disease; sCR: CR and normal FLC ratio and no clonal cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours, \>90% decrease in the difference between involved and uninvolved FLC levels; PR: \>=50% reduction of serum M-Protein and reduction in urinary M-protein by \>=90% or to \<200 mg/24 hours; \>=50% decrease in the difference between involved and uninvolved FLC levels in place of M-protein criteria or \>=50% reduction in plasma cells in place of M-protein if present at baseline.

    Time frame: From the date of randomization to date of death from any cause (maximum duration: 97 weeks)

Secondary outcomes

  1. Pharmacokinetic (PK) Assessment: Phase 1: Plasma Concentration of Isatuximab Observed at the End of an Intravenous Infusion (Ceoi)

    Ceoi was defined as the plasma concentration of Isatuximab at end of infusion. Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow). Analysis was performed on PK population: participants who gave informed consent, received at least one dose (even if incomplete) of isatuximab, had an assessable PK parameter.

    Time frame: Cycle 1 Day 1 and Cycle 3 Day 1: At the end of infusion

  2. PK Assessment: Phase 1: Maximum Observed Plasma Concentration (Cmax) of Isatuximab

    Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow). Analysis was performed on PK population.

    Time frame: For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 168 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 168 hr post-infusion

  3. PK Assessment: Phase 1: Time to Reach Maximum Plasma Concentration Observed (Tmax) of Isatuximab

    Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow). Analysis was performed on PK population.

    Time frame: For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 168 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 168 hr post-infusion

  4. PK Assessment: Phase 1: Plasma Concentration of Isatuximab at Week 1, 2 and 3

    Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow).

    Time frame: Week 1, 2 and 3

  5. PK Assessment: Phase 1: Predicted Cumulative Area Under the Plasma Concentration Curve (AUC) of Isatuximab Over the First Week (0-168 Hours) (AUC1W)

    Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow).

    Time frame: For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 168 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 168 hr post-infusion

  6. PK Assessment: Phase 1: Predicted Cumulative Area Under the Plasma Concentration Curve (AUC) of Isatuximab Over the First 2 Weeks (0-336 Hours) (AUC2W)

    Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow).

    Time frame: For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 336 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 336 hr post-infusion

  7. Pharmacodynamic (PD) Assessment: Phase 1: Change From Baseline in Serum/Plasma Markers

    Serum/plasma markers included: tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1-β), interleukin 6 (IL-6) and interferon-gamma (IFN-Gamma). Due to change in planned analysis, data for high-sensitivity C-reactive protein (hs-CRP) and CD38 was not collected and analyzed.

    Time frame: Cycle 1 Day 1

  8. Immunogenicity Assessment: Phase 1: Number of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies (ADA) Response

    ADA response was categorized as: treatment induced and treatment boosted response. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period (defined as the time from the first isatuximab administration until end of Phase 1) in participants without preexisting ADA (defined as: ADA that were present in samples drawn before treatment), including participants without pre-treatment (before treatment) samples. Treatment boosted ADA was defined as pre-existing ADA that increased at least 2 titer steps between pre-treatment (before treatment) and post-treatment.

    Time frame: Up to 120 weeks

  9. Clinical Assessment: Phase 1: Percentage of Participants With Overall Response and Clinical Benefit: Assessed Using European Society for Blood and Marrow Transplantation (EBMT) Criteria

    OR defined as participants with complete response (CR) or partial response (PR) as best overall response (BOR). Clinical benefit: participants with minimal response (MR) or better as BOR. BOR: best sequential response from start of treatment through the entire study excluding any time point following start of other treatment. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates, no increase in size or number of lytic bone lesions. PR: \>=50% reduction of serum M-protein, reduction in 24 h urinary M-protein by \>=90% or \<200mg, \>=50% reduction in size/number of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions. MR: 25 to 49% reduction in serum M-protein, 50-89% reduction in 24h urine M-protein, 25-49% reduction in size of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions.

    Time frame: From the date of randomization to the date of first documentation of progression or death (due to any cause) (maximum duration: 120 weeks)

  10. Clinical Assessment: Phase 1: Duration of Response (DOR)

    DOR: time from first response (PR or better) to first documented tumor progression/death. Progression as per EBMT: \>25% increase in serum monoclonal paraprotein level, which must also be an absolute increase of \>= 5 g/l: confirmed by \>=1 repeated investigation; \>25% increase in 24h urinary light chain excretion, which must also be an absolute increase of \>=200 mg/24 h:confirmed by \>=1 repeated investigation; \>25% increase in plasma cells in a bone marrow aspirate/on trephine biopsy, which must also be an absolute increase of \>= 10%; definite increase in size of existing bone lesions/soft tissue plasmacytomas; development of new bone lesions/soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium \>11·5 mg/dl or 2·8 mmol/l) not attributable to any other cause. PR: \>=50% reduction of serum M-protein, reduction in 24h urinary M-protein by \>=90% or \<200mg, \>=50% reduction in size/number of soft tissue plasmacytomas, no increase in size/number of lytic bone lesions.

    Time frame: From the date of first response to the date of first documentation of progression or death (due to any cause) (maximum duration: 120 weeks)

  11. Clinical Assessment: Phase 1: Time to First Response (TTR)

    TTR was defined as the time from first dose of isatuximab to first response (PR or better). PR: \>=50% reduction of serum M-protein, reduction in 24 h urinary M-protein by \>=90% or \<200mg, \>=50% reduction in size/number of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions.

    Time frame: From the date of first dose administration to the date of first response or death (due to any cause) (maximum duration: 120 weeks)

  12. Clinical Assessment: Phase 1: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) (Karnofsky Performance Status)-Shift From Baseline Value to Best Value During Treatment

    ECOG performance status was measured on a 4 point scale to assess participant's performance status. 0=Normal, fully functional; 1=Fatigue without significant decrease in daily activity; 2=Fatigue with significant impairment of daily activities or bed rest \<50% of waking hours; 3=Bed rest/sitting \>50% of waking hours; 4=Bedridden or unable to care for self, where lower score indicated good performance status. Number of participants with Baseline ECOG PS score and corresponding changes to the best values (categorized as: Baseline ECOG 1, During Treatment ECOG 0; Baseline ECOG 2, During Treatment ECOG 0; Baseline ECOG 2, During Treatment ECOG 1) are reported.

    Time frame: At baseline, during treatment (Day 1 up to 120 weeks)

  13. Clinical Assessment: Phase 1: Number of Participants With Eastern Cooperative Oncology Group Performance Status (Karnofsky Performance Status)-Shift From Baseline Value to Worst Value During Treatment

    ECOG performance status was measured on a 4 point scale to assess participant's performance status. 0=Normal, fully functional; 1=Fatigue without significant decrease in daily activity; 2=Fatigue with significant impairment of daily activities or bed rest \<50% of waking hours; 3=Bed rest/sitting\>50% of waking hours; 4=Bedridden or unable to care for self, where higher score indicated worst performance status. Number of participants with Baseline ECOG PS score and corresponding changes to the worst values (categorized as: Baseline ECOG 0, During Treatment ECOG 1; Baseline ECOG 2, During Treatment ECOG 1; Baseline ECOG 0, During Treatment ECOG 2; Baseline ECOG 1, During Treatment ECOG 2; Baseline ECOG 0, During Treatment ECOG 3; Baseline ECOG 1, During Treatment ECOG 3; Baseline ECOG 2, During Treatment ECOG 3) are reported.

    Time frame: At baseline, during treatment (up to 120 weeks)

  14. Phase 2 Stage 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.

    Time frame: From Baseline up to 30 days after the last dose (maximum duration: 414 weeks for Stage 1a and 92 weeks for Stage 1b)

  15. Phase 2 Stage 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.

    Time frame: From Baseline up to 30 days after the last dose (maximum duration: 301 weeks)

  16. Phase 2 Stage 1: Duration of Response

    DOR:Time from date of 1st IAC determined response (\>= PR) that was subsequently confirmed, to date of first IAC determined PD/death, whichever happened earlier. updated IMWG criteria- PR:\>=50% decrease in difference between involved and uninvolved FLC levels in place of M-protein criteria or a \>=50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline a \>=50% reduction in size of soft tissue plasmacytomas; PD: Increase of 25% from lowest response value in any of following: Serum M-protein \>=0.5 g/dL absolute increase and/or urine M-protein \>=200 mg/24 hours absolute increase and/or \>10 mg/dL absolute increase in difference between involved and uninvolved FLC levels, \>=10% bone marrow plasma cells (PCs), development of new bone lesions/soft tissue plasmacytomas or definite increase in size of existing bone lesions/soft tissue plasmacytomas, development of hypercalcemia (corrected serum calcium \>11·5 mg/dl) attributed to PC proliferation disorder.

    Time frame: From the date of first response until disease progression or death or data cut-off (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)

  17. Phase 2 Stage 2: Duration of Response

    DOR: Time from date of 1st IAC determined response (\>= PR) that was subsequently confirmed, to date of 1st IAC determined PD or death, whichever happened earlier. As per updated IMWG criteria-PR: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. ≥50% decrease in difference between involved and uninvolved FLC levels in place of M-protein criteria or ≥50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline ≥50% reduction in size of soft tissue plasmacytomas; PD: Increase of \>25% from lowest response value in any one of following: Serum M-component (absolute increase must be \>0.5 g/dL)4 and/or Urine M-component (absolute increase must be \>200 mg/24 h) and/or \>10 mg/dL absolute increase in difference between involved and uninvolved FLC levels, \>=10% bone marrow plasma cell, development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) attributed solely to plasma cell proliferative disorder.

    Time frame: From the date of first response until disease progression or death or data cut-off (maximum duration: 97 weeks)

  18. Phase 2 Stage 1: Percentage of Participants With Clinical Benefit

    Clinical benefit: participants with sCR, CR, VGPR, PR or MR as per IMWG criteria, determined by IAC. CR: negative immunofixation on serum \& urine, disappearance of any soft tissue plasmacytomas,\<5% PCs in bone marrow aspirates. sCR: CR + normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. VGPR: serum \& urine M-component detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-component plus urine M-component level \<100mg/24hours; PR: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours, ≥50% decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria or a ≥50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline, ≥50% size reduction in soft tissue plasmacytomas. MR:\>=25 but \<49% reduction in serum M-protein, reduction in 24h urine M-protein by 50-89%, 25-49% size reduction in soft tissue plasmacytomas.

    Time frame: From the date of randomization to the date of first documentation of progression or death (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)

  19. Phase 2 Stage 2: Percentage of Participants With Clinical Benefit

    Clinical benefit:participants with sCR, CR, VGPR, PR or MR, per IMWG criteria, determined by IAC. CR:negative immunofixation on serum \& urine, disappearance of any soft tissue plasmacytomas,\<5% plasma cells in bone marrow aspirates,normal FLC ratio(0.26-1.65) in participants with only FLC disease.sCR:CR+normal FLC ratio, absence of clonal cells in bone marrow biopsy.VGPR:serum \& urine M-component detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-component plus urine M-component level \<100mg/24h/,\>=90% decrease in difference between involved and uninvolved FLC levels; PR:\>=50% reduction of serum M-protein, reduction in 24h urinary M-protein by \>=90%/\<200mg/24h,\>50% decrease in difference between involved and uninvolved FLC in place of M-protein criteria, \>=50% reduction in size/number of soft tissue plasmacytomas. MR:\>=25 but \<49% reduction in serum M-protein,reduction in 24h urine M-protein by 50-89%, 25-49% reduction in size of soft tissue plasmacytomas

    Time frame: From the date of randomization to the date of first documentation of progression or death (maximum duration: 97 weeks )

  20. Phase 2 Stage 1: Progression Free Survival (PFS)

    PFS was defined as the time interval from the date of first isatuximab administration to the date of the first IAC-confirmed disease progression (PD) or date of death due to any cause, whichever came first. As per IMWG criteria, PD: Increase of \> 25% from lowest response value in any one or more of the following: Serum M-component and/or (the absolute increase must be \> 0.5 g/dL), Urine M-component and/or (the absolute increase must be \> 200 mg/24 h), \> 10mg/dL decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria, \>10% absolute percentage of bone marrow plasma cell, definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas, development of hypercalcemia (corrected serum calcium \> 11.5 mg/dL or 2.65 mmol/L) that attributed solely to the plasma cell proliferative disorder. Analysis was performed by Kaplan-Meier method.

    Time frame: From the date of the first dose administration until progression or death, whichever occurred first (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)

  21. Phase 2 Stage 2: Progression Free Survival

    PFS was defined as the time interval from the date of first isatuximab administration to the date of the first IAC-confirmed disease progression or the date of death due to any cause, whichever came first. As per IMWG criteria, PD: Increase of \>25% from lowest response value in any one of the following: Serum M-component (the absolute increase must be \>0.5 g/dL)4 and/or Urine M-component (the absolute increase must be \>200 mg/24 h) and/or \>10 mg/dL decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria, ≥10% bone marrow plasma cell, development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) attributed solely to the plasma cell proliferative disorder. Analysis was performed by Kaplan-Meier method.

    Time frame: From the date of the first dose administration until progression or death, whichever occurred first (maximum duration: 97 weeks)

  22. Phase 2 Stage 1: Overall Survival (OS)

    OS was defined as the time interval from the date of first Isatuximab administration to death from any cause. Analysis was performed by Kaplan-Meier method.

    Time frame: From the date of randomization to date of death from any cause (maximum duration 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)

  23. Phase 2 Stage 2: Overall Survival

    OS was defined as the time interval from the date of first Isatuximab administration to death from any cause. Analysis was performed by Kaplan-Meier method.

    Time frame: From the date of randomization to date of death from any cause (maximum duration: 97 weeks)

  24. Phase 2 Stage 1: Change From Baseline in Health Related Quality of Life (HRQL) European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Scores: Global Health Status

    EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (fatigue, nausea/vomiting, pain) \& other single items. For each item, high score = high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health \& quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 \& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant.

    Time frame: Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10 and End of Treatment (EOT: anytime up to 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)

  25. Phase 2 Stage 1: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Specific Module With 20 Items (EORTC QLQ-MY20) Scores: Disease Symptom Subscale Score

    EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with MM. It has 4 subscales: body image, future perspective), and 2 symptoms scales (disease symptoms and side-effects of treatment). Disease symptoms subscale used 4-point scale ranged from 1= 'Not at All' to 4= 'Very Much'. Scores were averaged, and transformed to 0 -100 scale, where higher scores = more symptoms and lower health-related quality of life (HRQL) and lower score = less symptoms and more HRQL.

    Time frame: Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10 and EOT (anytime up to 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)

  26. Phase 2 Stage 1: Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D) Generic Health Status - Visual Analogue Scale Scores

    EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state.

    Time frame: Baseline, Day 1 of Cycles 4, 7, 10, 13, 16, 19, and EOT (anytime up to 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)

  27. Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 1 Week Interval

    Time frame: Pre-dose, at the end of infusion, 1 hour and 168 hours post dose on Day 1 of Cycle 1

  28. Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 2 Weeks Interval

    Time frame: Cycle 1, Day 1: pre-dose, at the end of infusion, 168 and 336 hours post-infusion

  29. Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 4 Weeks Interval

    Time frame: Cycle 1, Day 1: pre-dose, at the end of infusion, 168, 336, and 672 hours post-infusion

  30. Pharmacokinetic Assessment: Phase 2 Stage 2: Plasma Concentration of Isatuximab Before Treatment Administration (Ctrough)

    Time frame: At Days 7, 14 and 28

  31. Pharmacokinetic Assessment: Phase 2 Stage 2: Accumulation Ratio of Isatuximab Based on Ctrough

    Ctrough is the plasma concentration observed before treatment administration. For 1st category, the accumulation ratio was calculated by dividing Ctrough value of Cycle 2 Day 1 by Cycle 1 Day 8 and for second category, accumulation ratio was calculated by dividing Ctrough value of Cycle 4 Day 1 by Cycle 1 Day 8.

    Time frame: Cycle 2, Day 1; Cycle 1, Day 8; Cycle 4, Day 1

  32. Immunogenicity Assessment: Phase 2 Stage 2: Number of Participants With Anti-drug Antibodies to Isatuximab

    ADA response was categorized as: treatment induced and treatment boosted response. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period (defined as the time from the first isatuximab administration until end of Phase 2 Stage 2) in participants without preexisting ADA (defined as: ADA that were present in samples drawn before treatment), including participants without pre-treatment (before treatment) samples. Treatment boosted ADA was defined as pre-existing ADA that increased at least 2 titer steps between pre-treatment (before treatment) and post-treatment.

    Time frame: Up to 97 weeks

07

Results

Posted Apr 15, 2020

Participant flow

Study participants were involved in the study from 11 May 2010 at 59 centers in 18 countries. A total of 418 participants were screened, of which 351 participants were enrolled. A total of 67 participants had screen failures due to failure to meet inclusion criteria.

Phase 1 (120 Weeks)
Participant flow — Phase 1 (120 Weeks)
MilestonePhase1: Isatuximab <=1 mg/kg Every 2 Weeks (Q2W)Phase 1: Isatuximab 3mg/kg Q2WPhase 1: Isatuximab 5 mg/kg Q2WPhase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)Phase 1: Isatuximab 10 mg/kg Every Week (QW)Phase 1: Isatuximab 20 mg/kg Q2WPhase 1: Isatuximab 20 mg/kg QWPhase 2 Stage 1a: Isatuximab 3 mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10 mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4WPhase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2WPhase 2 Stage 2: Isatuximab AlonePhase 2 Stage 2: Isatuximab + Dexamethasone
Started16632618677000000
All treated (at) population16632618677000000
Completed16632618677000000
Not completed00000000000000
Phase 2 Stage 1(1a-414Weeks;1b-92Weeks)
Participant flow — Phase 2 Stage 1(1a-414Weeks;1b-92Weeks)
MilestonePhase1: Isatuximab <=1 mg/kg Every 2 Weeks (Q2W)Phase 1: Isatuximab 3mg/kg Q2WPhase 1: Isatuximab 5 mg/kg Q2WPhase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)Phase 1: Isatuximab 10 mg/kg Every Week (QW)Phase 1: Isatuximab 20 mg/kg Q2WPhase 1: Isatuximab 20 mg/kg QWPhase 2 Stage 1a: Isatuximab 3 mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10 mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4WPhase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2WPhase 2 Stage 2: Isatuximab AlonePhase 2 Stage 2: Isatuximab + Dexamethasone
Started000000002324252500
At population000000002324252500
Completed000000002324252500
Not completed00000000000000
Phase 2 Stage 2 (301 Weeks)
Participant flow — Phase 2 Stage 2 (301 Weeks)
MilestonePhase1: Isatuximab <=1 mg/kg Every 2 Weeks (Q2W)Phase 1: Isatuximab 3mg/kg Q2WPhase 1: Isatuximab 5 mg/kg Q2WPhase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)Phase 1: Isatuximab 10 mg/kg Every Week (QW)Phase 1: Isatuximab 20 mg/kg Q2WPhase 1: Isatuximab 20 mg/kg QWPhase 2 Stage 1a: Isatuximab 3 mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10 mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4WPhase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2WPhase 2 Stage 2: Isatuximab AlonePhase 2 Stage 2: Isatuximab + Dexamethasone
Started00000000000011055
At population00000000000010955
Completed00000000000010955
Not completed00000000000010
Withdrew: Enrolled, but not treated00000000000010

Outcome measures

PrimaryPhase 1: Number of Participants With Dose Limiting Toxicities (DLTs)

DLTs were assessed using the national cancer institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03. DLTs were defined as any Grade 3 or higher non-hematological toxicity (with the exception of allergic reaction/hypersensitivity), Grade 4 neutropenia and/or Grade 4 thrombocytopenia lasting longer than 5 days, attributed to isatuximab. Any other toxicity that the Investigator and the Sponsor deemed to be dose-limiting, regardless of the grade, was also considered as DLT.

Time frame:
Day 1 of Cycle 1 up to Day 14 of Cycle 2
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsPhase 1:Isatuximab <=1 mg/kg Q2WPhase 1: Isatuximab 3mg/kg Q2WPhase 1: Isatuximab 5mg/kg Q2WPhase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)Phase 1: Isatuximab 10 mg/kg QWPhase 1: Isatuximab 20mg/kg Q2WPhase 1: Isatuximab 20mg/kg QW
Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)1100000
PrimaryPhase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.

Time frame:
From Baseline up to 30 days after the last dose (maximum duration: 120 weeks )
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPhase 1: Isatuximab <=1mg/kg Q2WPhase 1: Isatuximab 3mg/kg Q2WPhase 1: Isatuximab 5mg/kg Q2WPhase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)Phase 1: Isatuximab 10 mg/kg QWPhase 1: Isatuximab 20mg/kg Q2WPhase 1: Isatuximab 20mg/kg QW
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)16632618676
PrimaryPhase 2 Stage 1: Percentage of Participants With Overall Response (OR) According to International Myeloma Working Group (IMWG) Uniform Response Criteria

OR defined as participants with stringent complete response (sCR) or complete response (CR) or very good partial response (VGPR) or partial response (PR) . Based on IMWG, CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and \<=5% plasma cells in bone marrow; sCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; PR: \>=50% reduction of serum M-Protein and reduction in urinary M-protein by \>=90% or to \<200 mg/24 hours; \>=50% decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria or a \>=50% reduction in plasma cells in place of M-protein if present at baseline.

Time frame:
From the date of randomization until disease progression or death or data cut-off (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for Stage 1b arm)
Reported as:
Number · percentage of participants
Phase 2 Stage 1: Percentage of Participants With Overall Response (OR) According to International Myeloma Working Group (IMWG) Uniform Response Criteria
percentage of participantsPhase 2 Stage 1a: Isatuximab 3 mg/kgPhase 2 Stage 1a: Isatuximab 10 mg/kgPhase 2 Stage 1a: Isatuximab 10mg/kg Q2W and Then Q4WPhase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W
Phase 2 Stage 1: Percentage of Participants With Overall Response (OR) According to International Myeloma Working Group (IMWG) Uniform Response Criteria4.329.220.024.0
PrimaryPhase 2 Stage 2: Percentage of Participants With Overall Response According to Updated IMWG Response Criteria

OR: participants with sCR or CR or VGPR or PR. As per updated IMWG, CR: Negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \<=5% plasma cells in bone marrow; normal FLC ratio of 0.26-1.65 in participants with only FLC disease; sCR: CR and normal FLC ratio and no clonal cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours, \>90% decrease in the difference between involved and uninvolved FLC levels; PR: \>=50% reduction of serum M-Protein and reduction in urinary M-protein by \>=90% or to \<200 mg/24 hours; \>=50% decrease in the difference between involved and uninvolved FLC levels in place of M-protein criteria or \>=50% reduction in plasma cells in place of M-protein if present at baseline.

Time frame:
From the date of randomization to date of death from any cause (maximum duration: 97 weeks)
Reported as:
Number · percentage of participants
Phase 2 Stage 2: Percentage of Participants With Overall Response According to Updated IMWG Response Criteria
percentage of participantsPhase 2 Stage 2: Isatuximab AlonePhase 2 Stage 2: Isatuximab + Dexamethasone
Phase 2 Stage 2: Percentage of Participants With Overall Response According to Updated IMWG Response Criteria23.943.6
SecondaryPharmacokinetic (PK) Assessment: Phase 1: Plasma Concentration of Isatuximab Observed at the End of an Intravenous Infusion (Ceoi)

Ceoi was defined as the plasma concentration of Isatuximab at end of infusion. Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow). Analysis was performed on PK population: participants who gave informed consent, received at least one dose (even if incomplete) of isatuximab, had an assessable PK parameter.

Time frame:
Cycle 1 Day 1 and Cycle 3 Day 1: At the end of infusion
Reported as:
Mean · microgram per milliliter (mcg/mL)
Pharmacokinetic (PK) Assessment: Phase 1: Plasma Concentration of Isatuximab Observed at the End of an Intravenous Infusion (Ceoi)
microgram per milliliter (mcg/mL)Phase 1: Isatuximab 0.3 mg/kg Q2WPhase 1: Isatuximab 1 mg/kg Q2WPhase 1: Isatuximab 3mg/kg Q2WPhase 1: Isatuximab 5mg/kg Q2WPhase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)Phase 1: Isatuximab 20mg/kg Q2WPhase 1: Isatuximab 10mg/kg QWPhase 1: Isatuximab 20mg/kg QW
Cycle 1 Day 12.08667 ± 0.6556713.18333 ± 5.7446444.22500 ± 15.30651125.50000 ± 53.03301171.43333 ± 50.18853148.80000 ± 18.48513400.33333 ± 52.51984173.33333 ± 20.64784334.33333 ± 98.28462
Cycle 3 Day 1———————299.82500 ± 220.83898715.33333 ± 188.01241
SecondaryPK Assessment: Phase 1: Maximum Observed Plasma Concentration (Cmax) of Isatuximab

Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow). Analysis was performed on PK population.

Time frame:
For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 168 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 168 hr post-infusion
Reported as:
Geometric mean · mcg/mL
PK Assessment: Phase 1: Maximum Observed Plasma Concentration (Cmax) of Isatuximab
mcg/mLPhase 1: Isatuximab 0.3 mg/kg Q2WPhase 1: Isatuximab 1 mg/kg Q2WPhase 1: Isatuximab 3mg/kg Q2WPhase 1: Isatuximab 5mg/kg Q2WPhase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)Phase 1: Isatuximab 20mg/kg Q2WPhase 1: Isatuximab 10mg/kg QWPhase 1: Isatuximab 20mg/kg QW
Cycle 1 Day 12.00 ± 3112.4 ± 4553.7 ± 28126 ± NA181 ± 48154 ± 13457 ± 28181 ± 20343 ± 29
Cycle 3 Day 1———————265 ± 67712 ± 27
SecondaryPK Assessment: Phase 1: Time to Reach Maximum Plasma Concentration Observed (Tmax) of Isatuximab

Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow). Analysis was performed on PK population.

Time frame:
For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 168 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 168 hr post-infusion
Reported as:
Median · hours
PK Assessment: Phase 1: Time to Reach Maximum Plasma Concentration Observed (Tmax) of Isatuximab
hoursPhase 1: Isatuximab 0.3 mg/kg Q2WPhase 1: Isatuximab 1 mg/kg Q2WPhase 1: Isatuximab 3mg/kg Q2WPhase 1: Isatuximab 5mg/kg Q2WPhase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)Phase 1: Isatuximab 20mg/kg Q2WPhase 1: Isatuximab 10mg/kg QWPhase 1: Isatuximab 20mg/kg QW
Cycle 1 Day 12.49 (1.42 to 3.43)4.35 (3.13 to 6.33)6.99 (4.58 to 8.00)7.65 (5.13 to 10.17)4.28 (2.15 to 9.37)4.92 (2.60 to 30.08)5.87 (5.78 to 9.90)2.25 (2.20 to 7.50)6.83 (3.98 to 10.53)
Cycle 3 Day 1———————4.30 (2.57 to 27.48)8.07 (2.87 to 29.03)
SecondaryPK Assessment: Phase 1: Plasma Concentration of Isatuximab at Week 1, 2 and 3

Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow).

Time frame:
Week 1, 2 and 3
Reported as:
Geometric mean · mcg/mL
PK Assessment: Phase 1: Plasma Concentration of Isatuximab at Week 1, 2 and 3
mcg/mLPhase 1: Isatuximab 1 mg/kg Q2WPhase 1: Isatuximab 3mg/kg Q2WPhase 1: 5mg/kg Q2WPhase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)Phase 1: Isatuximab 10 mg/kg QWPhase 1: Isatuximab 20mg/kg Q2WPhase 1: Isatuximab 20mg/kg QW
Week 10.00223 ± 861.44 ± 8515.3 ± 9027.6 ± 8144.2 ± 5220.7 ± 63113 ± 37108 ± 33
Week 20.000800 ± 1730.181 ± 1361.39 ± 1161.97 ± 1458.31 ± 7755.1 ± 6363.9 ± 46194.8 ± 36
Week 30.000283 ± 1450.460 ± 12142.7 ± 734.18 ± 13318.6 ± 7175.9 ± 7891.0 ± 52347.3 ± 36
SecondaryPK Assessment: Phase 1: Predicted Cumulative Area Under the Plasma Concentration Curve (AUC) of Isatuximab Over the First Week (0-168 Hours) (AUC1W)

Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow).

Time frame:
For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 168 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 168 hr post-infusion
Reported as:
Geometric mean · mcg*hour/mL
PK Assessment: Phase 1: Predicted Cumulative Area Under the Plasma Concentration Curve (AUC) of Isatuximab Over the First Week (0-168 Hours) (AUC1W)
mcg*hour/mLPhase 1: Isatuximab 1 mg/kg Q2WPhase 1: Isatuximab 3mg/kg Q2WPhase 1: Isatuximab 5mg/kg Q2WPhase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)Phase 1: Isatuximab 10mg/kg QWPhase 1: Isatuximab 20mg/kg Q2WPhase 1: Isatuximab 20mg/kg QW
PK Assessment: Phase 1: Predicted Cumulative Area Under the Plasma Concentration Curve (AUC) of Isatuximab Over the First Week (0-168 Hours) (AUC1W)222 ± 802624 ± 247174 ± 5411566 ± 4813480 ± 3812680 ± 3532739 ± 2828405 ± 27
SecondaryPK Assessment: Phase 1: Predicted Cumulative Area Under the Plasma Concentration Curve (AUC) of Isatuximab Over the First 2 Weeks (0-336 Hours) (AUC2W)

Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow).

Time frame:
For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 336 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 336 hr post-infusion
Reported as:
Geometric mean · mcg*hour/mL
PK Assessment: Phase 1: Predicted Cumulative Area Under the Plasma Concentration Curve (AUC) of Isatuximab Over the First 2 Weeks (0-336 Hours) (AUC2W)
mcg*hour/mLPhase 1: Isatuximab 1 mg/kg Q2WPhase 1: Isatuximab 3mg/kg Q2WPhase 1: Isatuximab 5mg/kg Q2WPhase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)Phase 1: Isatuximab 10mg/kg QWPhase 1: Isatuximab 20mg/kg Q2WPhase 1: Isatuximab 20mg/kg QW
PK Assessment: Phase 1: Predicted Cumulative Area Under the Plasma Concentration Curve (AUC) of Isatuximab Over the First 2 Weeks (0-336 Hours) (AUC2W)222 ± 803076 ± 359546 ± 7014876 ± 6418967 ± 4430187 ± 4048003 ± 3171174 ± 29
SecondaryPharmacodynamic (PD) Assessment: Phase 1: Change From Baseline in Serum/Plasma Markers

Serum/plasma markers included: tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1-β), interleukin 6 (IL-6) and interferon-gamma (IFN-Gamma). Due to change in planned analysis, data for high-sensitivity C-reactive protein (hs-CRP) and CD38 was not collected and analyzed.

Time frame:
Cycle 1 Day 1
Reported as:
Mean · picogram/milliliter (pg/mL)
Pharmacodynamic (PD) Assessment: Phase 1: Change From Baseline in Serum/Plasma Markers
picogram/milliliter (pg/mL)Phase 1:Isatuximab <=1 mg/kg Q2WPhase 1: Isatuximab 3mg/kg Q2WPhase 1: Isatuximab 5mg/kg Q2WPhase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)Phase 1: Isatuximab 10mg/kg QWPhase 1: Isatuximab 20mg/kg Q2WPhase 1: Isatuximab 20mg/kg QW
TNF alpha163.181 ± 253.373179.783 ± 191.455352.974 ± 220.394340.799 ± 341.100503.462 ± 479.813342.664 ± 410.245307.319 ± 398.025412.541 ± 243.169
IL-1 Beta64.577 ± 227.39929.741 ± 55.5157.527 ± 8.118299.058 ± 572.260547.770 ± 1454.175327.957 ± 759.305305.914 ± 621.754293.307 ± 612.746
IL-6139.234 ± 212.385261.732 ± 270.11973.899 ± 53.211148.594 ± 175.719173.004 ± 433.297-8.109 ± 45.845274.616 ± 234.752165.295 ± 203.451
IFN Gamma477.116 ± 1673.0635.376 ± 9.31225.806 ± 44.698445.772 ± 1043.982568.806 ± 1022.000627.089 ± 1527.647448.387 ± 569.4991487.097 ± 2693.826
SecondaryImmunogenicity Assessment: Phase 1: Number of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies (ADA) Response

ADA response was categorized as: treatment induced and treatment boosted response. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period (defined as the time from the first isatuximab administration until end of Phase 1) in participants without preexisting ADA (defined as: ADA that were present in samples drawn before treatment), including participants without pre-treatment (before treatment) samples. Treatment boosted ADA was defined as pre-existing ADA that increased at least 2 titer steps between pre-treatment (before treatment) and post-treatment.

Time frame:
Up to 120 weeks
Reported as:
Count of participants · Participants
Immunogenicity Assessment: Phase 1: Number of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies (ADA) Response
ParticipantsPhase 1:Isatuximab <=1 mg/kg Q2WPhase 1: Isatuximab 3mg/kg Q2WPhase 1: Isatuximab 5mg/kg Q2WPhase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)Phase 1: Isatuximab 10mg/kg QWPhase 1: Isatuximab 20mg/kg Q2WPhase 1: Isatuximab 20mg/kg QW
Treatment-induced ADA20011111
Treatment boosted ADA00000000
SecondaryClinical Assessment: Phase 1: Percentage of Participants With Overall Response and Clinical Benefit: Assessed Using European Society for Blood and Marrow Transplantation (EBMT) Criteria

OR defined as participants with complete response (CR) or partial response (PR) as best overall response (BOR). Clinical benefit: participants with minimal response (MR) or better as BOR. BOR: best sequential response from start of treatment through the entire study excluding any time point following start of other treatment. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates, no increase in size or number of lytic bone lesions. PR: \>=50% reduction of serum M-protein, reduction in 24 h urinary M-protein by \>=90% or \<200mg, \>=50% reduction in size/number of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions. MR: 25 to 49% reduction in serum M-protein, 50-89% reduction in 24h urine M-protein, 25-49% reduction in size of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions.

Time frame:
From the date of randomization to the date of first documentation of progression or death (due to any cause) (maximum duration: 120 weeks)
Reported as:
Number · percentage of participants
Clinical Assessment: Phase 1: Percentage of Participants With Overall Response and Clinical Benefit: Assessed Using European Society for Blood and Marrow Transplantation (EBMT) Criteria
percentage of participantsPhase 1: Isatuximab 1mg/kg Q2WPhase 1: Isatuximab 3mg/kg Q2WPhase 1: Isatuximab 5mg/kg Q2WPhase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)Phase 1: Isatuximab 10mg/kg QWPhase 1: Isatuximab 20mg/kg Q2WPhase 1: Isatuximab 20mg/kg QW
OR33.3033.328.016.733.314.328.6
Clinical benefit33.320.033.328.027.833.328.642.9
SecondaryClinical Assessment: Phase 1: Duration of Response (DOR)

DOR: time from first response (PR or better) to first documented tumor progression/death. Progression as per EBMT: \>25% increase in serum monoclonal paraprotein level, which must also be an absolute increase of \>= 5 g/l: confirmed by \>=1 repeated investigation; \>25% increase in 24h urinary light chain excretion, which must also be an absolute increase of \>=200 mg/24 h:confirmed by \>=1 repeated investigation; \>25% increase in plasma cells in a bone marrow aspirate/on trephine biopsy, which must also be an absolute increase of \>= 10%; definite increase in size of existing bone lesions/soft tissue plasmacytomas; development of new bone lesions/soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium \>11·5 mg/dl or 2·8 mmol/l) not attributable to any other cause. PR: \>=50% reduction of serum M-protein, reduction in 24h urinary M-protein by \>=90% or \<200mg, \>=50% reduction in size/number of soft tissue plasmacytomas, no increase in size/number of lytic bone lesions.

Time frame:
From the date of first response to the date of first documentation of progression or death (due to any cause) (maximum duration: 120 weeks)
Reported as:
Mean · months
Clinical Assessment: Phase 1: Duration of Response (DOR)
monthsPhase 1: Isatuximab 1mg/kg Q2WPhase 1: Isatuximab 5mg/kg Q2WPhase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)Phase 1: Isatuximab 10mg/kg QWPhase 1: Isatuximab 20mg/kg Q2WPhase 1: Isatuximab 20mg/kg QW
Clinical Assessment: Phase 1: Duration of Response (DOR)20.217.165.76 ± 4.6210.70 ± 11.2514.31 ± 7.503.948.82 ± 7.83
SecondaryClinical Assessment: Phase 1: Time to First Response (TTR)

TTR was defined as the time from first dose of isatuximab to first response (PR or better). PR: \>=50% reduction of serum M-protein, reduction in 24 h urinary M-protein by \>=90% or \<200mg, \>=50% reduction in size/number of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions.

Time frame:
From the date of first dose administration to the date of first response or death (due to any cause) (maximum duration: 120 weeks)
Reported as:
Mean · months
Clinical Assessment: Phase 1: Time to First Response (TTR)
monthsPhase 1: Isatuximab 1mg/kg Q2WPhase 1: Isatuximab 5mg/kg Q2WPhase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)Phase 1: Isatuximab 10mg/kg QWPhase 1: Isatuximab 20mg/kg Q2WPhase 1: Isatuximab 20mg/kg QW
Clinical Assessment: Phase 1: Time to First Response (TTR)0.956.412.52 ± 3.771.96 ± 1.721.38 ± 0.651.181.46 ± 0.77
SecondaryClinical Assessment: Phase 1: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) (Karnofsky Performance Status)-Shift From Baseline Value to Best Value During Treatment

ECOG performance status was measured on a 4 point scale to assess participant's performance status. 0=Normal, fully functional; 1=Fatigue without significant decrease in daily activity; 2=Fatigue with significant impairment of daily activities or bed rest \<50% of waking hours; 3=Bed rest/sitting \>50% of waking hours; 4=Bedridden or unable to care for self, where lower score indicated good performance status. Number of participants with Baseline ECOG PS score and corresponding changes to the best values (categorized as: Baseline ECOG 1, During Treatment ECOG 0; Baseline ECOG 2, During Treatment ECOG 0; Baseline ECOG 2, During Treatment ECOG 1) are reported.

Time frame:
At baseline, during treatment (Day 1 up to 120 weeks)
Reported as:
Count of participants · Participants
Clinical Assessment: Phase 1: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) (Karnofsky Performance Status)-Shift From Baseline Value to Best Value During Treatment
ParticipantsPhase 1: Isatuximab
Baseline ECOG 1, During Treatment ECOG 011
Baseline ECOG 2, During Treatment ECOG 02
Baseline ECOG 2, During Treatment ECOG 111
SecondaryClinical Assessment: Phase 1: Number of Participants With Eastern Cooperative Oncology Group Performance Status (Karnofsky Performance Status)-Shift From Baseline Value to Worst Value During Treatment

ECOG performance status was measured on a 4 point scale to assess participant's performance status. 0=Normal, fully functional; 1=Fatigue without significant decrease in daily activity; 2=Fatigue with significant impairment of daily activities or bed rest \<50% of waking hours; 3=Bed rest/sitting\>50% of waking hours; 4=Bedridden or unable to care for self, where higher score indicated worst performance status. Number of participants with Baseline ECOG PS score and corresponding changes to the worst values (categorized as: Baseline ECOG 0, During Treatment ECOG 1; Baseline ECOG 2, During Treatment ECOG 1; Baseline ECOG 0, During Treatment ECOG 2; Baseline ECOG 1, During Treatment ECOG 2; Baseline ECOG 0, During Treatment ECOG 3; Baseline ECOG 1, During Treatment ECOG 3; Baseline ECOG 2, During Treatment ECOG 3) are reported.

Time frame:
At baseline, during treatment (up to 120 weeks)
Reported as:
Count of participants · Participants
Clinical Assessment: Phase 1: Number of Participants With Eastern Cooperative Oncology Group Performance Status (Karnofsky Performance Status)-Shift From Baseline Value to Worst Value During Treatment
ParticipantsPhase 1: Isatuximab
Baseline ECOG 0, During Treatment ECOG 18
Baseline ECOG 2, During Treatment ECOG 11
Baseline ECOG 0, During Treatment ECOG 23
Baseline ECOG 1, During Treatment ECOG 220
Baseline ECOG 0, During Treatment ECOG 31
Baseline ECOG 1, During Treatment ECOG 32
Baseline ECOG 2, During Treatment ECOG 31
SecondaryPhase 2 Stage 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.

Time frame:
From Baseline up to 30 days after the last dose (maximum duration: 414 weeks for Stage 1a and 92 weeks for Stage 1b)
Reported as:
Count of participants · Participants
Phase 2 Stage 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPhase 2 Stage 1a: Isatuximab 3mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4WPhase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W
Phase 2 Stage 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)22242525
SecondaryPhase 2 Stage 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.

Time frame:
From Baseline up to 30 days after the last dose (maximum duration: 301 weeks)
Reported as:
Count of participants · Participants
Phase 2 Stage 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPhase 2 Stage 2: Isatuximab AlonePhase 2 Stage 2: Isatuximab + Dexamethasone
Phase 2 Stage 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)10151
SecondaryPhase 2 Stage 1: Duration of Response

DOR:Time from date of 1st IAC determined response (\>= PR) that was subsequently confirmed, to date of first IAC determined PD/death, whichever happened earlier. updated IMWG criteria- PR:\>=50% decrease in difference between involved and uninvolved FLC levels in place of M-protein criteria or a \>=50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline a \>=50% reduction in size of soft tissue plasmacytomas; PD: Increase of 25% from lowest response value in any of following: Serum M-protein \>=0.5 g/dL absolute increase and/or urine M-protein \>=200 mg/24 hours absolute increase and/or \>10 mg/dL absolute increase in difference between involved and uninvolved FLC levels, \>=10% bone marrow plasma cells (PCs), development of new bone lesions/soft tissue plasmacytomas or definite increase in size of existing bone lesions/soft tissue plasmacytomas, development of hypercalcemia (corrected serum calcium \>11·5 mg/dl) attributed to PC proliferation disorder.

Time frame:
From the date of first response until disease progression or death or data cut-off (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
Reported as:
Mean · months
Phase 2 Stage 1: Duration of Response
monthsPhase 2 Stage 1a: Isatuximab 3mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4WPhase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W
Phase 2 Stage 1: Duration of Response1.9111.17 ± 5.777.31 ± 3.658.11 ± 2.33
SecondaryPhase 2 Stage 2: Duration of Response

DOR: Time from date of 1st IAC determined response (\>= PR) that was subsequently confirmed, to date of 1st IAC determined PD or death, whichever happened earlier. As per updated IMWG criteria-PR: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. ≥50% decrease in difference between involved and uninvolved FLC levels in place of M-protein criteria or ≥50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline ≥50% reduction in size of soft tissue plasmacytomas; PD: Increase of \>25% from lowest response value in any one of following: Serum M-component (absolute increase must be \>0.5 g/dL)4 and/or Urine M-component (absolute increase must be \>200 mg/24 h) and/or \>10 mg/dL absolute increase in difference between involved and uninvolved FLC levels, \>=10% bone marrow plasma cell, development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) attributed solely to plasma cell proliferative disorder.

Time frame:
From the date of first response until disease progression or death or data cut-off (maximum duration: 97 weeks)
Reported as:
Mean · months
Phase 2 Stage 2: Duration of Response
monthsPhase 2 Stage 2: Isatuximab AlonePhase 2 Stage 2: Isatuximab + Dexamethasone
Phase 2 Stage 2: Duration of Response8.6 ± 5.210.9 ± 4.6
SecondaryPhase 2 Stage 1: Percentage of Participants With Clinical Benefit

Clinical benefit: participants with sCR, CR, VGPR, PR or MR as per IMWG criteria, determined by IAC. CR: negative immunofixation on serum \& urine, disappearance of any soft tissue plasmacytomas,\<5% PCs in bone marrow aspirates. sCR: CR + normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. VGPR: serum \& urine M-component detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-component plus urine M-component level \<100mg/24hours; PR: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours, ≥50% decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria or a ≥50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline, ≥50% size reduction in soft tissue plasmacytomas. MR:\>=25 but \<49% reduction in serum M-protein, reduction in 24h urine M-protein by 50-89%, 25-49% size reduction in soft tissue plasmacytomas.

Time frame:
From the date of randomization to the date of first documentation of progression or death (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
Reported as:
Number · percentage of participants
Phase 2 Stage 1: Percentage of Participants With Clinical Benefit
percentage of participantsPhase 2 Stage 1a: Isatuximab 3mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4WPhase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W
Phase 2 Stage 1: Percentage of Participants With Clinical Benefit4.341.732.036.0
SecondaryPhase 2 Stage 2: Percentage of Participants With Clinical Benefit

Clinical benefit:participants with sCR, CR, VGPR, PR or MR, per IMWG criteria, determined by IAC. CR:negative immunofixation on serum \& urine, disappearance of any soft tissue plasmacytomas,\<5% plasma cells in bone marrow aspirates,normal FLC ratio(0.26-1.65) in participants with only FLC disease.sCR:CR+normal FLC ratio, absence of clonal cells in bone marrow biopsy.VGPR:serum \& urine M-component detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-component plus urine M-component level \<100mg/24h/,\>=90% decrease in difference between involved and uninvolved FLC levels; PR:\>=50% reduction of serum M-protein, reduction in 24h urinary M-protein by \>=90%/\<200mg/24h,\>50% decrease in difference between involved and uninvolved FLC in place of M-protein criteria, \>=50% reduction in size/number of soft tissue plasmacytomas. MR:\>=25 but \<49% reduction in serum M-protein,reduction in 24h urine M-protein by 50-89%, 25-49% reduction in size of soft tissue plasmacytomas

Time frame:
From the date of randomization to the date of first documentation of progression or death (maximum duration: 97 weeks )
Reported as:
Number · percentage of participants
Phase 2 Stage 2: Percentage of Participants With Clinical Benefit
percentage of participantsPhase 2 Stage 2: Isatuximab AlonePhase 2 Stage 2: Isatuximab + Dexamethasone
Phase 2 Stage 2: Percentage of Participants With Clinical Benefit43.154.5
SecondaryPhase 2 Stage 1: Progression Free Survival (PFS)

PFS was defined as the time interval from the date of first isatuximab administration to the date of the first IAC-confirmed disease progression (PD) or date of death due to any cause, whichever came first. As per IMWG criteria, PD: Increase of \> 25% from lowest response value in any one or more of the following: Serum M-component and/or (the absolute increase must be \> 0.5 g/dL), Urine M-component and/or (the absolute increase must be \> 200 mg/24 h), \> 10mg/dL decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria, \>10% absolute percentage of bone marrow plasma cell, definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas, development of hypercalcemia (corrected serum calcium \> 11.5 mg/dL or 2.65 mmol/L) that attributed solely to the plasma cell proliferative disorder. Analysis was performed by Kaplan-Meier method.

Time frame:
From the date of the first dose administration until progression or death, whichever occurred first (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
Reported as:
Median · months
Phase 2 Stage 1: Progression Free Survival (PFS)
monthsPhase 2 Stage 1a: Isatuximab 3mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4WPhase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W
Phase 2 Stage 1: Progression Free Survival (PFS)2.1 (1.02 to 5.49)9.6 (2.23 to NA)4.4 (1.84 to 5.82)3.6 (1.91 to 9.20)
SecondaryPhase 2 Stage 2: Progression Free Survival

PFS was defined as the time interval from the date of first isatuximab administration to the date of the first IAC-confirmed disease progression or the date of death due to any cause, whichever came first. As per IMWG criteria, PD: Increase of \>25% from lowest response value in any one of the following: Serum M-component (the absolute increase must be \>0.5 g/dL)4 and/or Urine M-component (the absolute increase must be \>200 mg/24 h) and/or \>10 mg/dL decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria, ≥10% bone marrow plasma cell, development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) attributed solely to the plasma cell proliferative disorder. Analysis was performed by Kaplan-Meier method.

Time frame:
From the date of the first dose administration until progression or death, whichever occurred first (maximum duration: 97 weeks)
Reported as:
Median · months
Phase 2 Stage 2: Progression Free Survival
monthsPhase 2 Stage 2: Isatuximab AlonePhase 2 Stage 2: Isatuximab + Dexamethasone
Phase 2 Stage 2: Progression Free Survival4.86 (3.877 to 7.688)10.15 (4.862 to 17.347)
SecondaryPhase 2 Stage 1: Overall Survival (OS)

OS was defined as the time interval from the date of first Isatuximab administration to death from any cause. Analysis was performed by Kaplan-Meier method.

Time frame:
From the date of randomization to date of death from any cause (maximum duration 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
Reported as:
Median · months
Phase 2 Stage 1: Overall Survival (OS)
monthsPhase 2 Stage 1a: Isatuximab 3mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4WPhase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W
Phase 2 Stage 1: Overall Survival (OS)15.277 (4.7310 to NA)18.628 (7.7536 to 20.1068)NA (8.4435 to NA)NA (8.3450 to NA)
SecondaryPhase 2 Stage 2: Overall Survival

OS was defined as the time interval from the date of first Isatuximab administration to death from any cause. Analysis was performed by Kaplan-Meier method.

Time frame:
From the date of randomization to date of death from any cause (maximum duration: 97 weeks)
Reported as:
Median · months
Phase 2 Stage 2: Overall Survival
monthsPhase 2 Stage 2: Isatuximab AlonePhase 2 Stage 2: Isatuximab + Dexamethasone
Phase 2 Stage 2: Overall Survival18.92 (13.602 to 23.064)17.25 (15.409 to NA)
SecondaryPhase 2 Stage 1: Change From Baseline in Health Related Quality of Life (HRQL) European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Scores: Global Health Status

EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (fatigue, nausea/vomiting, pain) \& other single items. For each item, high score = high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health \& quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 \& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant.

Time frame:
Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10 and End of Treatment (EOT: anytime up to 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
Reported as:
Mean · score on a scale
Phase 2 Stage 1: Change From Baseline in Health Related Quality of Life (HRQL) European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Scores: Global Health Status
score on a scalePhase 2 Stage 1a: Isatuximab 3mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4WPhase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W
Cycle 2 day 1-8.33 ± 20.152.22 ± 16.51-3.95 ± 20.670.00 ± 15.39
Cycle 3 day 10.00 ± 19.25-0.76 ± 16.446.55 ± 19.66-2.08 ± 15.54
Cycle 4 day 10.00 ± 24.53-5.30 ± 21.506.06 ± 21.117.41 ± 8.78
Cycle 5 day 10.00 ± 24.530.69 ± 15.276.48 ± 21.155.00 ± 4.56
Cycle 6 day 112.50 ± 14.43-10.19 ± 25.275.95 ± 13.3610.42 ± 7.98
Cycle 7 day 112.50 ± 5.89-3.57 ± 15.858.33 ± 11.796.67 ± 6.97
Cycle 8 day 10.00 ± 35.36-11.11 ± 18.764.17 ± 15.966.25 ± 10.49
Cycle 9 day 1-8.33 ± 11.79-10.00 ± 19.904.17 ± 14.436.25 ± 10.49
Cycle 10 day 1-8.33 ± 35.36-16.67 ± 22.058.33 ± 11.793.33 ± 7.45
End of treatment3.33 ± 33.64-11.67 ± 13.94-11.11 ± 20.97-12.50 ± 5.89
SecondaryPhase 2 Stage 1: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Specific Module With 20 Items (EORTC QLQ-MY20) Scores: Disease Symptom Subscale Score

EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with MM. It has 4 subscales: body image, future perspective), and 2 symptoms scales (disease symptoms and side-effects of treatment). Disease symptoms subscale used 4-point scale ranged from 1= 'Not at All' to 4= 'Very Much'. Scores were averaged, and transformed to 0 -100 scale, where higher scores = more symptoms and lower health-related quality of life (HRQL) and lower score = less symptoms and more HRQL.

Time frame:
Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10 and EOT (anytime up to 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
Reported as:
Mean · score on a scale
Phase 2 Stage 1: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Specific Module With 20 Items (EORTC QLQ-MY20) Scores: Disease Symptom Subscale Score
score on a scalePhase 2 Stage 1a: Isatuximab 3mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4WPhase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W
Cycle 2 day 15.56 ± 18.36-3.42 ± 11.240.93 ± 13.912.61 ± 18.75
Cycle 3 day 17.94 ± 11.94-5.05 ± 14.15-5.98 ± 16.89-1.52 ± 13.17
Cycle 4 day 18.33 ± 13.22-3.89 ± 16.98-10.00 ± 16.930.62 ± 30.10
Cycle 5 day 1-6.94 ± 10.520.51 ± 19.95-9.03 ± 17.04-6.67 ± 17.74
Cycle 6 day 18.33 ± 7.171.23 ± 23.53-15.08 ± 20.96-6.94 ± 10.52
Cycle 7 day 12.78 ± 3.93-3.70 ± 22.95-18.06 ± 21.93-11.11 ± 11.79
Cycle 8 day 1-5.56 ± 7.86-2.78 ± 23.50-15.28 ± 23.30-4.17 ± 5.32
Cycle 9 day 15.56 ± 7.86-10.00 ± 10.69-16.67 ± 29.75-6.94 ± 12.32
Cycle 10 day 10.00 ± 0.000.00 ± 19.25-15.28 ± 30.56-6.67 ± 17.30
End of treatment-9.72 ± 19.447.78 ± 24.4124.07 ± 22.4525.00 ± 35.36
SecondaryPhase 2 Stage 1: Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D) Generic Health Status - Visual Analogue Scale Scores

EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state.

Time frame:
Baseline, Day 1 of Cycles 4, 7, 10, 13, 16, 19, and EOT (anytime up to 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
Reported as:
Mean · score on a scale
Phase 2 Stage 1: Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D) Generic Health Status - Visual Analogue Scale Scores
score on a scalePhase 2 Stage 1a: Isatuximab 3mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4WPhase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W
Cycle 4 day 1-5.75 ± 18.552.00 ± 16.88-4.78 ± 15.714.89 ± 16.02
Cycle 7 day 1-2.50 ± 0.71-6.00 ± 27.399.00 ± 18.251.00 ± 7.94
Cycle 10 day 10.50 ± 2.12-10.33 ± 9.2910.33 ± 24.38-2.60 ± 8.11
Cycle 13 day 114.00 ± 19.80-5.00 ± 4.00-9.00-5.00
Cycle 16 day 15.00 ± 5.660.67 ± 23.71——
Cycle 19 day 1—-5.50 ± 4.95——
End of treatment-18.50 ± 16.98-11.60 ± 11.37-10.00 ± 9.54-9.00 ± 0.00
SecondaryPharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 1 Week Interval
Time frame:
Pre-dose, at the end of infusion, 1 hour and 168 hours post dose on Day 1 of Cycle 1
Reported as:
Geometric mean · mcg*hour/mL
Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 1 Week Interval
mcg*hour/mLPhase 2 Stage 2: Isatuximab AlonePhase 2 Stage 2: Isatuximab + Dexamethasone
Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 1 Week Interval37096 ± 8035423 ± 88
SecondaryPharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 2 Weeks Interval
Time frame:
Cycle 1, Day 1: pre-dose, at the end of infusion, 168 and 336 hours post-infusion
Reported as:
Geometric mean · mcg*hour/mL
Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 2 Weeks Interval
mcg*hour/mLPhase 2 Stage 2: Isatuximab AlonePhase 2 Stage 2: Isatuximab + Dexamethasone
Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 2 Weeks Interval91271 ± 7886761 ± 77
SecondaryPharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 4 Weeks Interval
Time frame:
Cycle 1, Day 1: pre-dose, at the end of infusion, 168, 336, and 672 hours post-infusion
Reported as:
Geometric mean · mcg*hour/mL
Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 4 Weeks Interval
mcg*hour/mLPhase 2 Stage 2: Isatuximab AlonePhase 2 Stage 2: Isatuximab + Dexamethasone
Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 4 Weeks Interval236360 ± 72226372 ± 66
SecondaryPharmacokinetic Assessment: Phase 2 Stage 2: Plasma Concentration of Isatuximab Before Treatment Administration (Ctrough)
Time frame:
At Days 7, 14 and 28
Reported as:
Geometric mean · mcg/mL
Pharmacokinetic Assessment: Phase 2 Stage 2: Plasma Concentration of Isatuximab Before Treatment Administration (Ctrough)
mcg/mLPhase 2 Stage 2: Isatuximab AlonePhase 2 Stage 2: Isatuximab + Dexamethasone
Day 7137 ± 75128 ± 54
Day 14230 ± 70214 ± 57
Day 28360 ± 63305 ± 66
SecondaryPharmacokinetic Assessment: Phase 2 Stage 2: Accumulation Ratio of Isatuximab Based on Ctrough

Ctrough is the plasma concentration observed before treatment administration. For 1st category, the accumulation ratio was calculated by dividing Ctrough value of Cycle 2 Day 1 by Cycle 1 Day 8 and for second category, accumulation ratio was calculated by dividing Ctrough value of Cycle 4 Day 1 by Cycle 1 Day 8.

Time frame:
Cycle 2, Day 1; Cycle 1, Day 8; Cycle 4, Day 1
Reported as:
Mean · ratio
Pharmacokinetic Assessment: Phase 2 Stage 2: Accumulation Ratio of Isatuximab Based on Ctrough
ratioPhase 2 Stage 2: Isatuximab AlonePhase 2 Stage 2: Isatuximab + Dexamethasone
Cycle 2 Day 1/Cycle 1 Day 8521.38338 ± 4891.633903.24370 ± 1.73860
Cycle 4 Day 1/Cycle 1 Day 83.58378 ± 2.773983.95950 ± 3.19310
SecondaryImmunogenicity Assessment: Phase 2 Stage 2: Number of Participants With Anti-drug Antibodies to Isatuximab

ADA response was categorized as: treatment induced and treatment boosted response. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period (defined as the time from the first isatuximab administration until end of Phase 2 Stage 2) in participants without preexisting ADA (defined as: ADA that were present in samples drawn before treatment), including participants without pre-treatment (before treatment) samples. Treatment boosted ADA was defined as pre-existing ADA that increased at least 2 titer steps between pre-treatment (before treatment) and post-treatment.

Time frame:
Up to 97 weeks
Reported as:
Count of participants · Participants
Immunogenicity Assessment: Phase 2 Stage 2: Number of Participants With Anti-drug Antibodies to Isatuximab
ParticipantsPhase 2 Stage 2: Isatuximab AlonePhase 2 Stage 2: Isatuximab + Dexamethasone
Treatment induced ADA10
Treatment boosted ADA00

Adverse events

Collected over All AEs were collected from signing of the informed consent form up to 30 days from last administration of study treatment (maximum exposure up to 120 weeks for Phase 1, 414 weeks for Phase 2 Stage 1a, 92 weeks for Phase 2 Stage 1b, and 301 weeks for Phase 2 Stage 2) regardless of seriousness or relationship to investigational product. All-cause mortality (Deaths) was collected for the entire study duration, 683 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Isatuximab <=1 mg/kg Q2W5/16 (31.3%)3/16 (18.8%)16/16 (100%)
Phase 1: Isatuximab 3mg/kg Q2W1/6 (16.7%)3/6 (50%)6/6 (100%)
Phase 1: Isatuximab 5mg/kg Q2W0/3 (0%)1/3 (33.3%)3/3 (100%)
Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)0/26 (0%)10/26 (38.5%)26/26 (100%)
Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)2/18 (11.1%)10/18 (55.6%)18/18 (100%)
Phase 1: Isatuximab 10mg/kg QW2/6 (33.3%)3/6 (50%)6/6 (100%)
Phase 1: Isatuximab 20mg/kg Q2W2/7 (28.6%)3/7 (42.9%)6/7 (85.7%)
Phase 1: Isatuximab 20mg/kg QW0/7 (0%)3/7 (42.9%)6/7 (85.7%)
Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W11/23 (47.8%)13/23 (56.5%)22/23 (95.7%)
Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W13/24 (54.2%)11/24 (45.8%)23/24 (95.8%)
Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W11/25 (44%)10/25 (40%)25/25 (100%)
Phase 2 Stage 1b: Isatuximab 20 mg/kg QW and Then Q2W11/25 (44%)9/25 (36%)24/25 (96%)
Phase 2 Stage 2: Isatuximab Alone56/109 (51.4%)52/109 (47.7%)92/109 (84.4%)
Phase 2 Stage 2: Isatuximab + Dexamethasone25/55 (45.5%)27/55 (49.1%)47/55 (85.5%)
Most frequent serious events
Showing 10 of 152
Most frequent serious events
EventPhase 1: Isatuximab <=1 mg/kg Q2WPhase 1: Isatuximab 3mg/kg Q2WPhase 1: Isatuximab 5mg/kg Q2WPhase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)Phase 1: Isatuximab 10mg/kg QWPhase 1: Isatuximab 20mg/kg Q2WPhase 1: Isatuximab 20mg/kg QWPhase 2 Stage 1a: Isatuximab 3mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4WPhase 2 Stage 1b: Isatuximab 20 mg/kg QW and Then Q2WPhase 2 Stage 2: Isatuximab AlonePhase 2 Stage 2: Isatuximab + Dexamethasone
Bone PainMusculoskeletal and connective tissue disorders0/160/61/30/261/180/60/70/70/230/240/251/251/1090/55
Disease ProgressionGeneral disorders1/160/60/30/260/180/60/70/74/230/241/251/257/1092/55
SepsisInfections and infestations0/160/60/32/261/180/60/70/74/231/240/250/253/1092/55
Atrial FibrillationCardiac disorders0/160/60/30/260/181/60/70/70/230/240/251/251/1090/55
Obstruction GastricGastrointestinal disorders0/160/60/30/260/181/60/70/70/230/240/250/250/1090/55
Small Intestinal ObstructionGastrointestinal disorders0/160/60/30/260/181/60/70/71/230/240/250/250/1092/55
PyrexiaGeneral disorders0/161/60/30/260/180/60/70/70/230/241/250/251/1091/55
Abdominal SepsisInfections and infestations0/161/60/30/260/180/60/70/70/230/240/250/250/1090/55
Haemophilus SepsisInfections and infestations0/160/60/30/260/181/60/70/70/230/240/250/250/1090/55
Pneumocystis Jirovecii PneumoniaInfections and infestations0/160/60/30/261/181/60/70/70/230/240/250/250/1090/55
Most frequent other events
Showing 10 of 196
Most frequent other events
EventPhase 1: Isatuximab <=1 mg/kg Q2WPhase 1: Isatuximab 3mg/kg Q2WPhase 1: Isatuximab 5mg/kg Q2WPhase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)Phase 1: Isatuximab 10mg/kg QWPhase 1: Isatuximab 20mg/kg Q2WPhase 1: Isatuximab 20mg/kg QWPhase 2 Stage 1a: Isatuximab 3mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4WPhase 2 Stage 1b: Isatuximab 20 mg/kg QW and Then Q2WPhase 2 Stage 2: Isatuximab AlonePhase 2 Stage 2: Isatuximab + Dexamethasone
ConstipationGastrointestinal disorders1/160/62/32/261/182/60/70/76/234/242/252/2511/1094/55
NauseaGastrointestinal disorders4/162/61/310/266/184/61/71/76/239/2411/257/2516/1097/55
FatigueGeneral disorders8/162/61/38/265/184/64/71/75/237/2411/259/2518/10911/55
Infusion Related ReactionInjury, poisoning and procedural complications5/163/62/312/2610/184/64/73/79/2313/2414/2515/2538/10920/55
Bone PainMusculoskeletal and connective tissue disorders2/160/62/34/263/180/60/70/71/233/241/252/2510/1091/55
Upper Respiratory Tract InfectionInfections and infestations1/161/61/37/263/183/63/71/74/237/249/256/2514/1098/55
CoughRespiratory, thoracic and mediastinal disorders3/162/61/36/262/183/61/72/72/2310/247/258/2519/10912/55
DyspnoeaRespiratory, thoracic and mediastinal disorders2/161/60/34/265/181/63/70/75/235/248/254/2517/1097/55
AnaemiaBlood and lymphatic system disorders6/162/60/310/264/181/60/70/79/233/248/258/254/1091/55
Back PainMusculoskeletal and connective tissue disorders1/160/61/36/267/181/60/71/72/237/243/253/2520/1099/55

Baseline characteristics

Analysis was performed on AT population.

Age, Continuous
Age, Continuous(years)Phase 1:Isatuximab <=1 mg/kg Q2WPhase 1: Isatuximab 3mg/kg Q2WPhase 1: Isatuximab 5 mg/kg Q2WPhase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)Phase 1: Isatuximab 10 mg/kg QWPhase 1: Isatuximab 20 mg/kg Q2WPhase 1: Isatuximab 20 mg/kg QWPhase 2 Stage 1a: Isatuximab 3 mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10 mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4WPhase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2WPhase 2 Stage 2: Isatuximab AlonePhase 2 Stage 2: Isatuximab + DexamethasoneTotal
Mean64.9 ± 11.663.5 ± 6.262.0 ± 3.565.0 ± 7.260.8 ± 12.661.7 ± 12.763.3 ± 10.060.0 ± 8.363.2 ± 8.963.9 ± 8.861.0 ± 7.361.1 ± 10.366.6 ± 8.866.3 ± 8.964.5 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1:Isatuximab <=1 mg/kg Q2WPhase 1: Isatuximab 3mg/kg Q2WPhase 1: Isatuximab 5 mg/kg Q2WPhase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)Phase 1: Isatuximab 10 mg/kg QWPhase 1: Isatuximab 20 mg/kg Q2WPhase 1: Isatuximab 20 mg/kg QWPhase 2 Stage 1a: Isatuximab 3 mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10 mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4WPhase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2WPhase 2 Stage 2: Isatuximab AlonePhase 2 Stage 2: Isatuximab + DexamethasoneTotal
Female53111922311117135826162
Male1132159454121318125129188
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1:Isatuximab <=1 mg/kg Q2WPhase 1: Isatuximab 3mg/kg Q2WPhase 1: Isatuximab 5 mg/kg Q2WPhase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)Phase 1: Isatuximab 10 mg/kg QWPhase 1: Isatuximab 20 mg/kg Q2WPhase 1: Isatuximab 20 mg/kg QWPhase 2 Stage 1a: Isatuximab 3 mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10 mg/kg Q2WPhase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4WPhase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2WPhase 2 Stage 2: Isatuximab AlonePhase 2 Stage 2: Isatuximab + DexamethasoneTotal
American Indian or Alaska Native000000000010203
Asian000020000001014
Native Hawaiian or Other Pacific Islander000000000100001
Black or African American0100100012435320
White14432013467211919219145287
More than one race000000000000000
Unknown or Not Reported21062210121011635
08

Study locations

59 sites
  • Mayo Clinic Site Number : 840003
    Scottsdale, Arizona 85054, United States
  • UCSF MS Center Site Number : 840005
    San Francisco, California 94117, United States
  • Emory University Site Number : 840009
    Atlanta, Georgia 30322, United States
  • University of Chicago Site Number : 840010
    Chicago, Illinois 60637, United States
  • The University Of Michigan Site Number : 840022
    Ann Arbor, Michigan 48109-0759, United States
  • Karmanos Cancer Center Site Number : 840027
    Detroit, Michigan 48201, United States
  • Mayo Clinic of Rochester Site Number : 840018
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine Site Number : 840013
    Saint Louis, Missouri 63110, United States
  • The Cancer Center At Hackensack University Medical Site Number : 840011
    Hackensack, New Jersey 07601, United States
  • Memorial Sloan-Kettering Cancer Center Site Number : 840014
    New York, New York 10021, United States
  • Duke University Medical College Site Number : 840016
    Durham, North Carolina 27707, United States
  • University of Cincinnati Site Number : 840004
    Cincinnati, Ohio 45267-0542, United States
  • Vanderbilt University Site Number : 840001
    Nashville, Tennessee 37232, United States
  • Huntsman Cancer Institute at the University of Utah Site Number : 840002
    Salt Lake City, Utah 84112-5550, United States
  • Fred Hutchinson Cancer Research Center Site Number : 840012
    Seattle, Washington 98109, United States
  • Medical College of Wisconsin Site Number : 840017
    Milwaukee, Wisconsin 53226, United States
  • Investigational Site Number : 032003
    Capital Federal, Buenos Aires C1425ASS, Argentina
  • Investigational Site Number : 032002
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1181ACH, Argentina
  • Investigational Site Number : 032001
    Ciudad de Buenos Aires, Buenos Aires C1426ANZ, Argentina
  • Investigational Site Number : 056001
    Antwerpen, 2060, Belgium
  • Hospital Mae de Deus Site Number : 076003
    Porto Alegre, Rio Grande Do Sul 90110-270, Brazil
  • Hospital de Amor - Hospital do Cancer de Barretos - Fundacao Pio XII Site Number : 076001
    Barretos, São Paulo 14784-400, Brazil
  • Clínica São Germano Site Number : 076002
    Sao Paulo, São Paulo 04537-081, Brazil
  • Instituto COI de Educacao e Pesquisa Site Number : 076004
    Rio De Janeiro, 22775-002, Brazil
  • Investigational Site Number : 152001
    Temuco, La Araucanía 4810469, Chile
  • Investigational Site Number : 246001
    Helsinki, 00029, Finland
  • Investigational Site Number : 246002
    Turku, 20520, Finland
  • Investigational Site Number : 250003
    Nantes Cedex 01, 44093, France
  • Investigational Site Number : 250004
    Pierre Benite, 69495, France
  • Investigational Site Number : 250001
    TOULOUSE Cedex 9, 31059, France
  • Investigational Site Number : 300001
    Athens, 11528, Greece
  • Investigational Site Number : 376004
    Jerusalem, 91120, Israel
  • Investigational Site Number : 376002
    Tel HaShomer, 52621, Israel
  • Investigational Site Number : 380001
    Bologna, 40138, Italy
  • Investigational Site Number : 380002
    Torino, 10126, Italy
  • Investigational Site Number : 484003
    San Luis Potosi, San Luis Potosí 78419, Mexico
  • Investigational Site Number : 484001
    Monterrey, 64460, Mexico
  • Investigational Site Number : 604001
    Arequipa, Peru
  • Investigational Site Number : 604002
    Lima, 34, Peru
  • Investigational Site Number : 643002
    Moscow, 125284, Russian Federation
  • Investigational Site Number : 643003
    Novosibirsk, 630087, Russian Federation
  • Investigational Site Number : 643001
    Petrozavodsk, 185019, Russian Federation
  • Investigational Site Number : 643004
    Saint-Petersburg, 194291, Russian Federation
  • Investigational Site Number : 724005
    Barcelona, Barcelona [Barcelona] 08036, Spain
  • Investigational Site Number : 724007
    Badalona, Catalunya [Cataluña] 08916, Spain
  • Investigational Site Number : 724002
    Pamplona, Navarra 31008, Spain
  • Investigational Site Number : 724006
    Valencia, Valenciana, Comunidad 46017, Spain
  • Investigational Site Number : 724004
    Madrid, 28041, Spain
  • Investigational Site Number : 724001
    Salamanca, 37007, Spain
  • Investigational Site Number : 724008
    Sevilla, 41013, Spain
  • Investigational Site Number : 792002
    Ankara, 06200, Turkey
  • Investigational Site Number : 792005
    Ankara, 06500, Turkey
  • Investigational Site Number : 792001
    İstanbul, Turkey
  • Investigational Site Number : 792004
    Samsun, 55139, Turkey
  • Investigational Site Number : 804001
    Kyiv, 04112, Ukraine
  • Investigational Site Number : 804004
    Vinnytsia, 21001, Ukraine
  • Investigational Site Number : 804002
    Zaporizhzhya, 69600, Ukraine
  • Investigational Site Number : 826002
    Southampton, Hampshire SO16 6YD, United Kingdom
  • Investigational Site Number : 826001
    Nottingham, Nottinghamshire NG5 1PB, United Kingdom
09

References and documents

Publications

  • Dimopoulos M, Bringhen S, Anttila P, Capra M, Cavo M, Cole C, Gasparetto C, Hungria V, Jenner M, Vorobyev V, Ruiz EY, Yin JY, Saleem R, Hellet M, Mace S, Paiva B, Vij R. Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. Blood. 2021 Mar 4;137(9):1154-1165. doi: 10.1182/blood.2020008209. PubMed 33080623 ↗
  • Mikhael J, Richter J, Vij R, Cole C, Zonder J, Kaufman JL, Bensinger W, Dimopoulos M, Lendvai N, Hari P, Ocio EM, Gasparetto C, Kumar S, Oprea C, Chiron M, Brillac C, Charpentier E, San-Miguel J, Martin T. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. Leukemia. 2020 Dec;34(12):3298-3309. doi: 10.1038/s41375-020-0857-2. Epub 2020 May 14. PubMed 32409691 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2010 to primary completion in Dec 2018, 103 months.

Results were first posted in Apr 2020, 1 year 3 months after primary completion. A results delay was requested in Dec 2019.

Of 64 phase 1/2 interventional studies under Hematologic Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 127. This study's 103 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2010
First posted
Mar 10, 2010
StartActual
May 11, 2010
Primary completionActual
Dec 21, 2018
CompletionActual
Jul 13, 2023
Results delay requested
Dec 7, 2019
Results first posted
Apr 15, 2020
Last update
Nov 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01084252
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 10, 2010
Start date
May 11, 2010
Primary completion
Dec 21, 2018
Completion
Jul 13, 2023
Results posted
Apr 15, 2020
Last update
Nov 1, 2024

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isatuximab

Start the discussion